G1 touts PhII can­cer da­ta, but shares tank on place­bo re­sults; Mer­ck bags an­oth­er ap­proved in­di­ca­tion for Keytru­da

→ G1 Ther­a­peu­tics $GTHX tried their lev­el best to tout the re­sults of their Phase II study of tri­laci­clib in com­bi­na­tion with topote­can for small …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.